November 2025

Innovative Minimally Invasive Glaucoma Treatments in Development Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Traditional treatments, such as eye drops and invasive surgeries, have limitations, including side effects and variable efficacy. However, recent advancements in medical technology are paving the way for minimally invasive glaucoma treatments (MIGS) that promise […]

Open Angle Glaucoma Clinical Trials 2025: FDA, EMA, and NICE Approvals Open-angle glaucoma (OAG) remains one of the leading causes of irreversible blindness worldwide. With an aging population and increasing prevalence, the demand for innovative treatments is higher than ever. The year 2025 is poised to be a landmark period for OAG clinical trials, with

Breakthrough Glaucoma Treatments Offer New Hope for Patients Glaucoma, often called the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. For years, treatment options were limited to eye drops, laser therapy, and invasive surgeries. However, recent advancements in medical science are revolutionizing how we manage this condition. Today, breakthrough glaucoma treatments

Sanoculis’ MINT® Glaucoma Treatment Secures CE Mark Approval A Breakthrough in Glaucoma Care Sanoculis has reached a major milestone after receiving CE Mark approval for its MINT® Glaucoma Treatment. This new technology introduces a minimally invasive way to manage glaucoma, helping reduce intraocular pressure (IOP) while protecting vision. Glaucoma remains one of the leading causes

How Fovea-Disc Distance Affects Glaucoma Scan Accuracy Glaucoma is a leading cause of irreversible blindness, and early detection is key to preventing vision loss. One of the main tools used to detect glaucoma is optical coherence tomography (OCT), which measures the thickness of the retinal nerve fiber layer (RNFL). However, scan accuracy can be affected

Perfuse Therapeutics to Present PER-001 Glaucoma Implant at ARVO Perfuse Therapeutics, a biotech company focused on advanced eye treatments, is set to present its new PER-001 glaucoma implant at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. This marks an important step in developing better, long-lasting solutions for glaucoma patients. Why

MINIject® Shows 5-Year Efficacy in Glaucoma Treatment Introduction Glaucoma is a leading cause of irreversible blindness worldwide. Managing it can be challenging, especially with treatments that require daily eye drops or invasive surgery. A promising solution is the MINIject® implant, which has shown sustained results over five years in the STAR-GLOBAL trial. This long-term data

Revolutionizing Glaucoma Treatment with Adaptive Trials and Patient Focus Glaucoma, a leading cause of irreversible blindness worldwide, has long been a challenge for both patients and healthcare providers. Traditional treatment approaches often follow a one-size-fits-all model, which may not account for individual patient variability. However, the future of glaucoma management is evolving with adaptive clinical